💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sotagliflozin

CHEMBL3039507 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
424.9 g/mol
LogP
3.2
Phase
4

Sotagliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor used for the reduction of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and type 2 diabetes with chronic kidney disease. By inhibiting both intestinal SGLT1 and renal SGLT2, it reduces glucose absorption and renal glucose reabsorption, lowers blood glucose, and reduces sodium retention with accompanying reductions in heart failure risk. Its dual mechanism provides complementary glycosuric and cardiorenal benefits.

น้ำหนักโมเลกุล

424.9000 g/mol

LogP

3.20

TPSA

104.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Chronic Kidney Disease Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Heart Failure Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H25ClO5S

                    

                    
                    

                        
HBD / HBA

                        
3 / 6

                    

                    
                    

                        
พันธะที่หมุนได้

                        
6

                    

                    
                    
                    

                        
อะตอมหนัก

                        
28

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
Sotagliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor used for the reduction of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and type 2 diabetes with chronic kidney disease. By inhibiting both intestinal SGLT1 and renal SGLT2, it reduces glucose absorption and renal glucose reabsorption, lowers blood glucose, and reduces sodium retention with accompanying reductions in heart failure risk. Its dual mechanism provides complementary glycosuric and cardiorenal benefits.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Sotagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3039507.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 24831714.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.